Performance of international prognostic indices in plasmablastic lymphoma: a comparative evaluation

ConclusionOur current observations support the use of the IPI and its enhanced derivatives in PBL patients. There is, however, a distinct requirement for novel prognostic tools to better delineate subgroups at risk for early relapse or refractory disease as well as late relapse. A comprehensive molecular characterization of a clinically annotated cohort of PBL patients is therefore urgently warranted.
Source: Journal of Cancer Research and Clinical Oncology - Category: Cancer & Oncology Source Type: research